朝藿定A在制备猪链球菌2型荚膜抑制剂中的应用
Chaohuoding A targets the gene clusters that synthesize the capsule of Streptococcus suis type 2, inhibiting capsule biosynthesis and solving the problems of drug resistance and capsule evasion of host immunity in Streptococcus suis type 2. It enhances the host's ability to clear bacteria and provides a new drug option for the treatment of Streptococcus suis type 2 infection.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JILIN UNIVERSITY
- Filing Date
- 2026-03-03
- Publication Date
- 2026-07-17
AI Technical Summary
The drug resistance of Streptococcus suis type 2 and the key role of its capsule in evading host immune recognition and clearance, coupled with the lack of effective capsule inhibitors in current technologies, have increased the difficulty of treatment.
Ascorbic acid A targets the capsule biosynthesis gene cluster of Streptococcus suis type 2, reduces the transcription level of capsule biosynthesis genes, inhibits capsule biosynthesis, and enhances the host's ability to clear bacteria.
This compound effectively inhibits the synthetic function of Streptococcus suis type 2 capsule, enhances the host's clearance of bacteria, and reduces bacterial pathogenicity, providing a new drug candidate compound for the treatment of Streptococcus suis type 2 infection.
Smart Images
Figure CN121754560B_ABST